Medium impact
Velaglucerase Alfa (VPRIV®)
BCBS Tennessee·Effective Oct 31, 2026
BlueCross BlueShield of Tennessee is implementing a new prior authorization requirement and coverage policy for Velaglucerase Alfa (VPRIV®), an enzyme replacement therapy for Gaucher disease types 1, 2, and 3. The policy requires step therapy, specialized prescriber credentials, baseline diagnostic testing, and clinical evidence of disease before initial approval; continuation therapy requires documented clinical benefit. This policy becomes effective October 31, 2026, and applies to all Tennessee members.